The sensitivities of the serum and bronchoalveolar lavage galactomannan (GM) assays in 48 patients with pulmonary aspergilloma were 38% (13 of 34; 95% confidence interval [CI], 22%-56%) and 92% (33 of 36; 95% CI, 78%-98%), respectively. The positivity of serum GM assays was significantly higher in patients with hemoptysis than in those without hemoptysis (52% vs 9%; P 5 .02).
The sensitivities of the serum and bronchoalveolar lavage galactomannan (GM) assays in 48 patients with pulmonary aspergilloma were 38% (13 of 34; 95% confidence interval [CI] , 22%-56%) and 92% (33 of 36; 95% CI, 78%-98%), respectively. The positivity of serum GM assays was significantly higher in patients with hemoptysis than in those without hemoptysis (52% vs 9%; P 5 .02).
Aspergillus is a ubiquitous fungus that causes a variety of clinical syndromes in the lung. The clinical syndrome and pathologic spectrum of Aspergillus lung disease are determined by the underlying lung architecture, the patient's immune response, and the number of organisms involved [1, 2] . This fungus can cause pulmonary aspergilloma (PA), chronic cavitary pulmonary aspergillosis (CCPA), and chronic necrotizing pulmonary aspergillosis (CNPA) in mildly immunocompromised individuals [2, 3] . Invasive pulmonary aspergillosis (IPA) is a severe and potentially fatal disease that occurs in immunocompromised patients [4] [5] [6] . Because early diagnosis of IPA may facilitate higher cure rates [5] , newer diagnostic platforms not based on fungal culture have been investigated. Galactomannan (GM), a component of fungal cell walls, is released during tissue invasion by Aspergillus hyphae and can be detected in body fluids [7] . GM assays of serum and bronchoalveolar lavage (BAL) fluid have been found to be useful in the diagnosis of IPA [4, 6, 7] . However, there have been few studies on the use of serum and BAL GM assays in patients with noninvasive forms of aspergillosis, such as PA [8] [9] [10] . We therefore evaluated the diagnostic usefulness of serum and BAL GM assays in patients with PA.
METHODS

Study Population
A retrospective cohort study was performed that involved all adult patients (aged >18 years) with PA who did not meet the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) host criteria [11] and who had a serum or BAL fluid specimen was assayed for GM from January 2008 through December 2009 at the Asan Medical Center, a 2700-bed, tertiary care hospital in Seoul, South Korea. Patients receiving piperacillin-tazobactam, amoxicillin-clavulanate, or ampicillin-sulbactam before serum or BAL GM assay were excluded, because these antibiotics can cause false-positive results of GM assays [12] .
Definition of PA
PA was defined as a single pulmonary cavity containing a fungal ball visualized on a chest radiograph or CT [1, 9] . Proven PA was defined as the microscopic demonstration in histologic specimens and/or isolation by culture of Aspergillus species in sputum, BAL fluid, or sterile material. In the absence of cultured Aspergillus species or microscopic demonstration in histologic specimens, patients were classified as having probable PA.
Serum and BAL GM Assays
Serum GM antigen was measured using enzyme-linked immunosorbent assay (Platelia Aspergillus; Bio-Rad) in all patients suspected of having aspergillosis. The decision to perform fiber-optic bronchoscopy and to obtain a BAL sample was made by the attending physician on the basis of each patient's initial clinical features and imaging data. During the study period, GM assays were routinely performed on BAL samples evaluated for pulmonary infiltrates. An optical density >.5 was considered to be positive for GM in serum or BAL samples [6, 7, 12] .
Statistical Analysis
Statistical analyses were performed using SPSS for Windows (version 12.0; SPSS). Categorical variables were compared using the Pearson v 2 test or Fisher's exact test. The McNemar test was used to compare the sensitivity of the different tests [13] . P < .05 was considered to be statistically significant.
RESULTS
Patient Characteristics
The study flow chart is shown in Figure 1 . A review of patient records identified 48 patients with PA; of these, 39 (81%) were classified as having proven PA and 9 (19%) as having probable PA. Patient baseline clinical characteristics are presented in Table 1 . Of these 48 patients, 36 (75%) had hemoptysis. Of the latter, 10 (28%) had massive hemoptysis and 26 (72%) had a history of recurrent hemoptysis.
Diagnostic Usefulness of Serum and BAL GM Assays and Aspergillus Culture
Serum GM assays were performed for 34 (71%) of the 48 patients with PA, and 36 (75%) underwent fiber-optic bronchoscopy with BAL ( Figure 1 ). The sensitivities of the serum and BAL GM assays were 38% (13 of 34; 95% confidence interval [CI], 22%-56%) and 92% (33 of 36; 95% CI, 78%-98%), respectively. The positivity of serum GM assays was significantly higher in patients with hemoptysis than in those without hemoptysis (52% vs 9%; P 5 .02).
Aspergillus culture was performed for 44 (92%) of the 48 patients, with a sensitivity of 43% (19 of 44; 95% CI, 26%-57%). None of these 44 patients was treated with an antifungal agent before Aspergillus culture. Among them, 35 cultures were performed using BAL fluid specimens and 9 using sputum specimens. Concurrent culture and BAL GM assays were performed for 35 patients, with BAL Aspergillus culture being significantly less sensitive than BAL GM assays (46% vs 91%; P , .001). Of the 19 patients (54%) with negative culture results, 17 (89%) had positive BAL GM assay results. Of the 16 patients (46%) with positive culture results, 15 (94%) had positive BAL GM assay results.
Serum and BAL GM assays and BAL Aspergillus culture were performed for 22 patients (Figure 1) . In this subgroup, the positivity of BAL GM assays (86%) was significantly higher than that of either serum GM assays (41%; P 5 .002) or culture (55%; P 5 .016) (Supplemental Table 1 ).
DISCUSSION
We evaluated the clinical usefulness of serum and BAL GM assays for patients with PA. We found that BAL GM assays were more sensitive than serum GM assays (92% [95% CI, 78%-98%] vs 38% [95% CI, 22%-56%]). To our knowledge, this is the first study to systematically evaluate the diagnostic usefulness of serum and BAL GM assays in patients with PA.
Our finding that serum GM assay results were positive for 13 (38%) of 34 patients with PA was similar to the positivity rate Figure 1 . Study flow chart. The EORTC/MSG host criteria were adopted from the previous study [11] . BAL, bronchoalveolar lavage; GM, galactomannan.
of 41% (5 of 12 patients) reported in a previous study [8] but higher than the rate of 22% (14 of 64) reported in another study [10] . The high rate that we observed may have been attributable to the high percentage of patients with hemoptysis. Indeed, we found that the positivity of serum GM assays was significantly higher in patients with hemoptysis than in those without hemoptysis (52% vs 9%; P 5 .02). This may be attributable to bleeding from the bronchial artery, enabling GM of colonizing Aspergillus to reach the circulation from the damaged vessel. This hypothesis is supported by a case report that showed that Aspergillus fumigatus could be isolated from the blood of a patient with PA after bronchial artery embolization caused by massive hemoptysis [14] . Alternatively, patients with slowly progressive PA, including those with intermediate or borderline PA, may show positivity on serum GM assays, because angioinvasive growth of Aspergillus might theoretically be required for antigens to be deposited in the bloodstream [7] . However, the GM assay is a measure of cell wall antigen and is not a test of organism invasion. Although microinvasion may occur along the edges of the lung cavities in aspergilloma, this was not demonstrated in present study.
Almost all patients with PA have serum Aspergillus precipitating antibodies [15] ; thus, the BAL GM assay is of limited value when the serum precipitin assay is available. Of interest, because the latter assay was not available in our hospital, the BAL GM assay revealed additional microbiologic evidence in 9 patients without microbiologic evidence of aspergillosis (9 probable aspergilloma) before BAL. In addition, in a small proportion of aspergilloma cases, serum Aspergillus precipitating antibodies may be falsely negative because of species other than A. fumigatus or to administration of corticosteroid therapy to the patient [2] . Thus, because sputum or BAL fungal cultures are of minor diagnostic value, the BAL GM assay may give useful microbiologic evidence if the serum precipitin assay is not available or negative. This hypothesis is supported by our finding that, of the 19 patients with negative culture results, 17 (89%) had positive BAL GM assay results.
The present study had several limitations. First, the cutoff value of optical density >.5 used to define positivity for GM in serum or BAL samples was derived from studies in immunocompromised patients for diagnosis of IPA [4] [5] [6] ; however, the optimal cutoff value of serum or BAL GM assays for diagnosis of PA in immunocompetent patients has not been evaluated. Further studies are needed to determine the optimal cutoff value for the GM assay and the diagnostic performance of assays using that cutoff in patients with PA. Second, PA is at the lower end of the clinical spectrum of aspergillosis. Some may argue that the presence of hemoptysis in 75% of the patients in the present study suggests that these patients with elevated GM levels actually represent a more acute end of the disease spectrum, such as CCPA or CNPA. However, in previous studies, 50%-85% of patients with PA had hemoptysis [15] . Although hemoptysis can be caused by direct invasion to adjacent blood vessels by Aspergillus, another possible mechanism for hemoptysis in patients with PA could be the mechanical action and associated friction of a mobile fungus ball, which causes bleeding from the hypervascular cavity wall [15] . We thus believe that hemoptysis is not exclusively associated with the advanced stage of aspergilloma or progression of aspergilloma to CCPA or CNPA. In addition, in the present study, 26 (54%) of 48 patients with PA received a diagnosis on the basis of histopathologic examination, which showed no evidence of local invasion of Aspergillus in these patients. Furthermore, we defined PA as a single pulmonary cavity containing a fungus ball; thus, patients with CCPA, which is characterized by the formation and expansion of multiple cavities, should not have been included in the present study. Third, there may have been a selection bias because concurrent serum and BAL GM assays were performed in only 22 (46%) of the 48 study patients. However, subgroup analysis in these 22 patients showed that the sensitivities of the serum and BAL GM assays (41% and 86%, respectively) were similar to those in the entire study population (38% and 92%, respectively), suggesting that selection bias did not substantially affect our results. Finally, a previous report indicated that, in addition to piperacillin-tazobactam, amoxicillin-clavulanate, and ampicillin-sulbactam, other antibiotics may be associated with false-positive GM assay results [16] . Although we excluded patients receiving piperacillin-tazobactam, amoxicillinclavulanate, and ampicillin-sulbactam before GM assays to exclude possible false-positive GM results, 7 (15%) of 48 patients received other antibiotics 1 week before GM assay. Therefore, it is possible that these antibiotics may have resulted in false-positive GM assay results.
In conclusion, serum GM assay results may be positive in patients with noninvasive forms of aspergillosis, such as PA, especially in patients with hemoptysis. In addition, BAL GM assays are more sensitive than are culture assays in patients with PA.
